Cell Biology
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human Interleukin-1 beta recombinant protein | Login | Human Interleukin-1 beta recombinant protein | ||||||||||||||||
|
||||||||||||||||||
| Human Myoglobin recombinant protein | Login | Human Myoglobin recombinant protein | ||||||||||||||||
|
||||||||||||||||||
| Human Programmed cell death protein 1 recombinant protein (PDCD1) | Login | Human Programmed cell death protein 1 recombinant protein (PDCD1) | ||||||||||||||||
|
||||||||||||||||||
| Human Tumor necrosis factor receptor superfamily member 1A (TNFR1A) recombinant protein | Login | Human Tumor necrosis factor receptor superfamily member 1A (TNFR1A) recombinant protein | ||||||||||||||||
|
||||||||||||||||||
| CD47 Protein - Mus musculus Leukocyte surface antigen CD47 recombinant protein | Login | CD47 Protein - Mus musculus Leukocyte surface antigen CD47 recombinant protein | ||||||||||||||||
|
||||||||||||||||||
| Vudalimab Biosimilar - Anti-CTLA4;PDCD1 mAb - Research Grade | Login | Vudalimab Biosimilar - Anti-CTLA4;PDCD1 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
| Vudalimab Biosimilar - Anti-CTLA4;PDCD1 mAb - Research Grade | Login | Vudalimab Biosimilar - Anti-CTLA4;PDCD1 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
| Bimekizumab Biosimilar - Anti-IL17A, IL17F mAb - Research Grade | Login | Bimekizumab Biosimilar - Anti-IL17A, IL17F mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
| Bimekizumab Biosimilar - Anti-IL17A, IL17F mAb - Research Grade | Login | Bimekizumab Biosimilar - Anti-IL17A, IL17F mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
| Nemolizumab Biosimilar - Anti-IL31RA mAb - Research Grade | Login | Nemolizumab Biosimilar - Anti-IL31RA mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
| Nemolizumab Biosimilar - Anti-IL31RA mAb - Research Grade | Login | Nemolizumab Biosimilar - Anti-IL31RA mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
| Secukinumab Biosimilar - Anti-IL17A mAb - Research Grade | Login | Secukinumab Biosimilar - Anti-IL17A mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
| Secukinumab Biosimilar - Anti-IL17A mAb - Research Grade | Login | Secukinumab Biosimilar - Anti-IL17A mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
| Enavatuzumab Biosimilar - Anti-TNFRSF12A, CD266 mAb - Research Grade | Login | Enavatuzumab Biosimilar - Anti-TNFRSF12A, CD266 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
| Enavatuzumab Biosimilar - Anti-TNFRSF12A, CD266 mAb - Research Grade | Login | Enavatuzumab Biosimilar - Anti-TNFRSF12A, CD266 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
| Brodalumab Biosimilar - Anti-IL17RA, CD217 mAb - Research Grade | Login | Brodalumab Biosimilar - Anti-IL17RA, CD217 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
| Brodalumab Biosimilar - Anti-IL17RA, CD217 mAb - Research Grade | Login | Brodalumab Biosimilar - Anti-IL17RA, CD217 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
| Vascular endothelial growth factor A(VEGFA) | Login | Vascular endothelial growth factor A(VEGFA) | ||||||||||||||||
|
||||||||||||||||||
| Tubulinyl-Tyr carboxypeptidase 2 (VASH2) | Login | Tubulinyl-Tyr carboxypeptidase 2 (VASH2) | ||||||||||||||||
|
||||||||||||||||||
| Interleukin-2(Il2) | Login | Interleukin-2(Il2) | ||||||||||||||||
|
||||||||||||||||||
| Creatine kinase MB(CKMB) | Login | Creatine kinase MB(CKMB) | ||||||||||||||||
|
||||||||||||||||||
| EGFR protein / Epidermal growth factor receptor(EGFR) | Login | EGFR protein / Epidermal growth factor receptor(EGFR) | ||||||||||||||||
|
||||||||||||||||||
| Fibrinogen-like protein 1(FGL1) | Login | Fibrinogen-like protein 1(FGL1) | ||||||||||||||||
|
||||||||||||||||||
| Galectin-9(LGALS9) | Login | Galectin-9(LGALS9) | ||||||||||||||||
|
||||||||||||||||||
| Human Interleukin-12 subunit beta(IL12B) | Login | Human Interleukin-12 subunit beta(IL12B) | ||||||||||||||||
|
||||||||||||||||||


